SAN DIEGO

,

Jan. 4, 2022

/PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from

January 10

– 13, 2022.

Chief Executive Officer

Saundra Pelletier

will provide an update on the commercialization of Evofem’s hormone-free contraceptive

Phexxi®

(lactic acid, citric acid and potassium bitartrate) as well as the Company’s pipeline, including the

ongoing Phase 3 clinical trial

evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and the recently announced

Multipurpose Prevention Technology (MPT) product candidate

for indications including the prevention of HIV in women.

The Company’s presentation will be available for on demand listening beginning at 7:00am ET on

Monday, January 10, 2022

through the H.C. Wainwright BioConnect conference portal and via

https://evofem.investorroom.com/HCWJan22

for 90 days.

To request a one-on-one meeting with Evofem during the conference, please contact your H.C. Wainwright representative or email

[email protected]

.

About Evofem Biosciences


Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia, gonorrhea and HIV). The Company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and

evofem.com

.

Phexxi

^®

is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact



Amy Raskopf


Evofem Biosciences, Inc.



[email protected]



Mobile: (917) 673-5775

View original content to download multimedia:

https://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-hc-wainwright-bioconnect-conference-301453189.html

SOURCE Evofem Biosciences, Inc.